Clinical Trial Update: Autologous Cell Suspension Grafting Using ReCell in Vitiligo and Piebaldism Patients [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating autologous cell suspension grafting using ReCell in patients with Segmental vitiligo and Piebaldism has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Piebaldism
• Segmental Vitiligo

Drugs mentioned

• RECELL (Autologous cell suspension)

Snippet

Sponsor: Netherlands Institute for Pigment Disorders | Conditions: Segmental Vitiligo, Piebaldism | Phase 4 | Status: COMPLETED